.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,235,576

« Back to Dashboard

Claims for Patent: 7,235,576

Title:Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Abstract:This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Inventor(s): Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Orange, CT), Khire; Uday (Hamden, CT), Lowinger; Timothy B. (Nishinomiya, JP), Scott; William J. (Guilford, CT), Smith; Roger A. (Madison, CT), Wood; Jill E. (Hamden, CT), Monahan; Mary-Katherine (Hamden, CT), Natero; Reina (Hamden, CT), Renick; Joel (Milford, CT), Sibley; Robert N. (North Haven, CT)
Assignee: Bayer Pharmaceuticals Corporation (West Haven, CT)
Application Number:10/042,203
Patent Claims: 1. A pharmaceutically acceptable salt of a compound selected from the group consisting of: N-(5-tert-butyl-2-methoxy phenyl)-N'-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea, N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-py- ridyloxy)phenyl)urea, N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-carbamoyl-4-pyridyloxy)ph- enyl)urea, N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea; N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(3-(2-(N-methylcarbam- oyl)-4-pyridyloxy)phenyl)urea and their pharmaceutically acceptable salts.

2. A pharmaceutically acceptable salt of the compound N-(5-tert-butyl-2-methoxy phenyl)-N'-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea.

3. A pharmaceutically acceptable salt of claim 2 selected from the group consisting of a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulpheric acid, phosphoric acid, methanesulphonic acid, triflurosulphonic acid, benzenesulfonic acid, p-tolune sulphonic acid(tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicyclic acid, phenylacetic acid, and mandelic acid; and b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

4. A pharmaceutically acceptable salt of the compound N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-py- ridyloxy)phenyl)urea.

5. A pharmaceutically acceptable salt of a compound which is: N-(2-methoxy-5-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00186## N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-carbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00187## N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00188## N-(2-methoxy-4-chloro-5-(trifloromethyl) phenyl)-N'-(3(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00189##

6. A pharmaceutically acceptable salt of the compound N-(4-chloro-3-(triflouromethyl)phenyl)-N'-(2carbamoyl-4-pyridyloxy)phenyl- )urea. -pyridyloxy)phenyl)urea.

7. A pharmaceutically acceptable salt which is the tosylate salt of N-(2-methoxy-5-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00190## N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-carbamoyl-4-pyridyloxy) phenyl) urea of the formula: ##STR00191## N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00192## N-(2-methoxy-4-chloro-5-(trifloromethyl) phenyl)-N'-(3(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00193##

8. A pharmaceutically acceptable salt of a compound which is: N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-carbamoyl-4-pyridyloxy) phenyl) urea of the formula: ##STR00194## N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00195## N-(2-methoxy-4-chloro-5-(trifloromethyl) phenyl)-N'-(3(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00196##

9. A pharmaceutically acceptable salt of claim 8 selected from the group consisting of a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

10. A pharmaceutically acceptable salt which is the tosylate salt of N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-carbamoyl-4-pyridyloxy) phenyl) urea of the formula: ##STR00197## N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00198## N-(2-methoxy-4-chloro-5-(trifloromethyl) phenyl)-N'-(3(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula: ##STR00199##

11. A pharmaceutically acceptable salt of claim 10 selected from the group consisting of a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

12. A method for the treatment of a cancerous cell growth mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of a compound selected from the group consisting of: N-(5-tert-butyl-2-methoxy phenyl)-N'-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea, N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-py- ridyloxy)phenyl)urea, N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-carbamoyl-4-pyridyloxy)ph- enyl)urea, N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea; N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(3-(2-(N-methylcarbam- oyl)4-pyridyloxy)phenyl)urea.

13. A method for the treatment of a cancerous cell growth as in claim 12 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of N-(5-tert-butyl-2-methoxy phenyl)-N'-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea.

14. A method for the treatment of a cancerous cell growth as in claim 12 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-py- ridyloxy)phenyl)urea.

15. A method for the treatment of a cancerous cell growth as in claim 12 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of N(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-carbamoyl-4-pyridyloxy)phe- nyl)urea.

16. A method for the treatment of a cancerous cell growth as in claim 12 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea.

17. A method for the treatment of a cancerous cell growth as in claim 12 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)N'-(3-(2-(N-methylcarbamo- yl)-4-pyridyloxy)phenyl)urea.

18. A method as in claim 12 for the treatment of solid cancers.

19. A method as in claim 12 for the treatment of carcinomas, myleoid disorders or adenomas.

20. A method as in claim 13 for the treatment of carcinomas, myleoid disorders or adenomas.

21. A method as in claim 14 for the treatment of carcinomas, myleoid disorders or adenomas.

22. A method as in claim 15 for the treatment of carcinomas, myleoid disorders or adenomas.

23. A method as in claim 16 for the treatment of carcinomas, myleoid disorders or adenomas.

24. A method as in claim 17 for the treatment of carcinomas, myleoid disorders or adenomas.

25. A method as in claim 12 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

26. A method as in claim 13 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

27. A method as in claim 14 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

28. A method as in claim 15 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

29. A method as in claim 16 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

30. A method as in claim 17 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

31. A method as in claim 12 for the treatment of myeloid leukemia or villous colon adenomas.

32. A method as in claim 13 for the treatment of myeloid leukemia or villous colon adenomas.

33. A method as in claim 14 for the treatment of myeloid leukemia or villous colon adenomas.

34. A method as in claim 15 for the treatment of myeloid leukemia or villous colon adenomas.

35. A method as in claim 16 for the treatment of myeloid leukemia or villous colon adenomas.

36. A method as in claim 17 for the treatment of myeloid leukemia or villous colon adenomas.

37. A method as in claim 12 wherein the pharmaceutically acceptable salt administered is selected from the group of salts consisting of a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

38. A method as in claim 13 where the pharmaceutical acceptable salt administered is the tosylate salt of N-(5-tert-butyl-2-methoxy phenyl)-N'-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea.

39. A method as in claim 14 where the pharmaceutical acceptable salt administered is the tosylate salt of N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbarmoyl)-4-p- yridyloxy)phenyl)urea.

40. A method as in claim 15 where the pharmaceutical acceptable salt administered is the tosylate salt of N-(4-chloro-3-(trifluromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyri- dyloxy)phenyl)urea.

41. A method as in claim 16 where the pharmaceutical acceptable salt administered is the tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea.

42. A method as in claim 17 where the pharmaceutical acceptable salt administered is the tosylate salt of N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(3-(2-(N-methylcarbam- oyl)-4-pyridyloxy)phenyl)urea.

43. A pharmaceutical acceptable salt as in claim 2 which is the tosylate salt of N-(5-tert-butyl-2-methoxy phenyl)-N'-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea.

44. A pharmaceutical acceptable salt as in claim 4 which is the tosylate salt of N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamo- yl)-4-pyridyloxy)phenyl)urea.

45. A pharmaceutical acceptable salt as in claim 6 which is the tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-carbamoyl-4-pyrid- yloxy)phenyl)urea.

46. A pharmaceutical acceptable salt as in claim 8 which is the tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoy- l)-4-pyridyloxy)phenyl)urea.

47. A pharmaceutical acceptable salt as in claim 10 which is the tosylate salt of N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(3-(2-(N-meth- ylcarbamoyl)-4-pyridyloxy)phenyl)urea.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc